Kathmere Capital Management, LLC Paratek Pharmaceuticals, Inc. Transaction History

Kathmere Capital Management, LLC

  • $1.06 Billion
  • Q4 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 24, 2023
BUY
$1.67 - $2.51 $50,100 - $75,300
30,000 New
30,000 $0

Others Institutions Holding PRTK

# of Institutions
4
Shares Held
1.54M
Call Options Held
0
Put Options Held
0
View Full List

About Paratek Pharmaceuticals, Inc.

PRTK Quotes by TradingView
  • Ticker PRTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,862,500
  • Description
  • Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...
More about PRTK
Track This Portfolio

Track Kathmere Capital Management, LLC Portfolio

Follow Kathmere Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kathmere Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Kathmere Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email